Myocardial Na,K-ATPase and digoxin therapy in human heart failure

Keld Kjeldsen*, Henning Bundgaard

*Corresponding author for this work

    Research output: Contribution to journalArticleResearchpeer-review


    The specific binding of digitalis glycosides to the Na,K-ATPase is used as a tool for Na,K-ATPase quantification with high accuracy and precision. In myocardial biopsies from patients with heart failure, total Na,K-ATPase concentration is decreased, and the decrease in Na,K-ATPase concentration correlates with a decrease in heart function. During digitalization, a fraction of remaining pumps are occupied by digoxin. No evidence for an endogenous digitalis-like factor of any clinical importance was obtained. It is recommended that digoxin be administered to heart failure patients who still have dyspnea after institution of mortality-reducing therapy.

    Original languageEnglish
    Pages (from-to)702-707
    Number of pages6
    JournalAnnals of the New York Academy of Sciences
    Publication statusPublished - 1 Jan 2003


    • Digoxin
    • Heart failure
    • Na,K-ATPase


    Explore the research areas of 'Myocardial Na,K-ATPase and digoxin therapy in human heart failure'.

    Cite this